What this means
This is a trial that has not reported results yet, so it does not show whether the approach works. It studies chemotherapy given before surgery for patients aged 70 or older.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 70 and over
- Where
- 1 site
The science
- Registered title
- Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More
- Trial ID
- NCT06293625 ↗
- Phase
- PHASE 3
- Study type
- interventional
- Conditions
- Colon Cancer
- What is tested
- Folfox, Surgery
- Sponsor
- Centre Hospitalier Universitaire Dijon
- Ages
- 70 Years to no maximum
- Dates
- First posted Mar 5, 2024 · updated Mar 30, 2025
Registry summary
Colon cancer (CC) is the 5th most common cancer worldwide. Standard care for locally advanced disease is surgical resection followed by 3-6 months of adjuvant chemotherapy (AC) with oxaliplatin and 5-fluorouracil (OxFp).
Almost all of these patients undergo surgery, but many do not receive AC due to frailty (following surgery). This particularly affects patients over 70, who represent the majority of patients diagnosed with CC.
FOxTROT 2, a trial to test the role of NAC in older patients.
Sites (1)
- CHU Dijon Bourgogne, Dijon, France